Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market cap should be atleast $1B IMO. 3 companies Premier Bio, Datatecnics ,HALB and ASU are working on this.
260 Million OS and non-dilutive funding on hand.
HALB should be atleast $4 per share IMO.
RAPID TEST - The University project for a rapid test to identify Covid-19 infection, from a sample such
as saliva, mucus, blood and CSF will be based upon the following two IP applications:
Method for Treating and Curing Covid-19 Infection , and Method for the Rapid
Identification of Covid-19 Infection.
https://halberdcorporation.com/wp-content/uploads/2020/09/ASU-K-Fully-Executed.pdf
NON DILUTIVE FUNDING - DEVELOPED ANTIBODY - CEO SAYS
Since I began at Halberd back in May, I have been working on assembling a talented team of technical and business leaders (who, like me, are willing to work for “out of the money” stock warrants as their sole compensation) and set the direction for research and development of detection and treatment of coronavirus.
Recruited the “Best-of-the-Best” from Premier Biomedical, Inc. to join Halberd Corporation. Their experience and dedication to bringing the technology to market allowed us to hit the ground running.
Appointed Dr. Mitchell S. Felder as a Consultant to the Scientific Advisory Board.
Patricio Reyes was appointed as Chief Technical Officer and Chairman of the Scientific Advisory Board.
Abdon Nanhay and Edson Brito, of Brazil, and Dr. Gregory George of Sharon Regional Hospital Network agreed to join our Scientific Advisory Board.
Carl Eller, Retired NFL Players Association President, agreed to serve as a consultant.
Secured license to two issued patents on an extracorporeal treatment process, previously held by Premier Biomedical.
Established Coronavirus as clinical target for extracorporeal patent application.
Secured license to three provisional patent applications for Coronavirus work.
Secured required non-dilutive funding to start work at a research facility.
Conducted and completed a search for an ideal university partner, selecting a world-class organization with outstanding research personnel.
Began working with our university partner on September 1, 2020, and established bi-weekly technology review meetings to track progress and guide research direction as needed.
Recently acquired license to a fourth provisional patent application targeting coronavirus prevention and treatment.
Developed a unique antibody that conjoins Covid disease antigens and has exceeded expectations in testing to date!
https://halberdcorporation.com/halberd-corporation-ceo-update-letter-october-2020/
https://www.biospace.com/article/releases/halberd-covid-19-preventative-nasal-spray-provisional-patent-application-filed/
Halberd COVID-19 Preventative Nasal Spray Provisional Patent Application Filed
Arizona State University/Halberd Develop Antibody Against Covid-19
The performance has exceeded expectations
Development continues toward three major potential utilizations of the antibody against the Coronavirus:
Preventative;
Diagnostic, and
Therapeutic Treatment.
https://api.quotemedia.com/supplement/news-story/?webmasterId=501&storyId=4986209306155857
OS is 260 million, blow out soon and coming weeks would take this to dollar land imo.
They are working to develop a nasal spray for preventing covid.
I am expecting company to file EUA soon.
RL*T* went up from 2 or 3 cents to almost a $ with 2.2 Billion OS.
This could run like that soon.They filed 3 provisional patents in 2020.
*Method for Treating and Curing Covid-19 Infection US 62/989981 03/16/2020 Provisional
*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients US 63/007207 04/08/2020 Provisional
*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus US 63/013104 4/21/2020 Provisional
*Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans US 63/080735 9/20/2020 Provisional
Utilization of Stents for the Treatment of Blood Borne Carcinomas US 13/128870 11/11/2009 Issued Patent US 8,758,287
Sequential Extracorporeal Treatment of Bodily Fluids US 13/254855 3/16/2010 Issued Patent US 9,216,386
In other words, should n't be atleast $1/share already?.
GNC SALE
GNC Cancels Auction, Pushes Forward With Sale to Chinese Sponsor
https://news.bloombergtax.com/bankruptcy-law/gnc-cancels-auction-pushes-forward-with-sale-to-chinese-sponsor
NEWS FROM AFRICA
Alternet Systems earns investment interest as Uber features African electric motorcycle market
http://www.africanreview.com/transport-a-logistics/vehicles/alternet-systems-earns-investment-interest-as-uber-features-african-electric-motorcycle-market
Investors buying at $0.05/share
ALYI has entered into a comprehensive funding agreement with RevoltTOKEN that includes an existing $25 million first tranche investment commitment at $0.05 per share. ALYI has initiated a $2.5 million draw down on the first $25 million to begin construction on a 100-acre facility in Africa.
Good news Firefighter is recovering better
https://z-m-www.facebook.com/groups/344854903191256/?hc_ref=ARSsFCltQ2lEiZCoj3iHAT770MzCnfzM_2jsf4BgjMQtSFrtAF1DVZf45zIO0NjfkM0&ref=nf_target
RLFTF UPGRADED TO OTCQB AND WILL BE MADE FILINGS WITH SEC TOO.
https://sec.report/otc/financial-report/256107
RLF-100 is the only drug with proven history and EXPANDED ACCESS.Results are expected this week or so.
https://clinicaltrials.gov/ct2/show/record/NCT04311697
HFD-Ventilator set at 65% after medication vs 100% yesterday
As per HFD facebook page, yesterday the ventilator was set at 100%,today the medication was given with no visible side effects and ventilator was set at 65%.Thats a big WOW in a day,IMO.
https://www.facebook.com/HFD-Politics-and-Firefighters-1948811568733074/
CBS is also part of Princeton meeting, so expect some coverage tomorrow or later this week,JMO.
Dr.JAVITT IS THE VICE CHAIR OF BOD OF RLFTF
https://www.businesswire.com/news/home/20200310006003/en/RELIEF-THERAPEUTICS-Holding-SA-RLF-announces-proposal
RELIEF THERAPEUTICS Holding SA (SIX: RLF) announces the proposal of Prof. Jonathan Javitt, M.D., M.P.H., at the upcoming general assembly as Vice Chairman of the Board
Javitt to guide development of RLF-100 (Aviptadil) for treatment of Coronavirus (COVID-19) induced Acute Respiratory Distress Syndrome
Coronavirus (COVID-19) death is primarily caused by Acute Respiratory Distress Syndrome (ARDS), in which severe inflammation causes the lungs to fill with fluid and even mechanical ventilation is unable to sustain life.
RELIEF THERAPEUTICS Holding SA owns Investigational New Drug licenses, Orphan Drug Designation, and patents covering the use of Aviptadil, in both the US and the EU, for treatment of Acute Respiratory Distress.
Aviptadil has a 20-year history of human safety and has been used extensively as a compounded drug for respiratory disorders.
In its current form, RLF-100 has non-clinical and early clinical data supporting its use for treatment of Acute Respiratory Distress, pulmonary inflammation induced by Sarcoidosis and Acute Lung Injury (e.g. smoke inhalation) as well as indicative data showing that RLF-100 is able to block pulmonary inflammation and edema formation in animal models.
Relief intends to initiate Phase 2b/3 studies as expeditiously as possible to treat ARDS in COVID-19 patients who otherwise have less than a 50% chance of survival.
CBS NEWS,PRINCETON,YALE & Dr.JAVITT CONFERENCE TOMORROW
https://princeton78.com/posts/feed.asp
This Sunday, August 16th, 2 pm ET; princeton78.com
(please note start time is different than the last 2 sessions)
What are the medical, pharmaceutical, and scientific communities doing to understand how COVID-19 operates, and to provide new treatments and vaccines that can lead us out of this pandemic?
Please join Stephen Chanock, Director of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), who currently leads a project to learn who is more at risk for COVID-19 and what kinds of outcomes certain people are likely to incur, and Jonathan Javitt, CEO of U.S.-Israel-based NeuroRX, which just started Phase 2/3 clinical trials of RLF-100, a drug for the treatment of respiratory distress in COVID-19 patients. This session will be moderated by Yale School of Medicine communicator and former CBS News producer and reporter Rob Forman. Log in at princeton78.com starting at 1:45 pm ET to catch up with classmates before we start the session!
As before, each session will run 78 minutes, and be a panel followed by a general discussion/Q&A. And all you need to do is login at the class website princeton78.com via Zoom – they’re free!
And we welcome your suggestions for topics. What would you would like to hear about, and which Classmates you would like to hear it from?
We look forward to you joining us.
Smokers is a Huge market - Protects lung cell injuries due smoking
RLF-100) is a formulation of synthetic human Vasoactive Intestinal Peptide, which is known to target the VPAC1 receptor of the ATII cell and to protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. The U.S. FDA granted Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19.
EXPANDED ACCESS WHEN NO COMPARABLE DRUG AVAILABLE
Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Expanded access may be appropriate when all the following apply:
Patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition.
There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
Patient enrollment in a clinical trial is not possible.
Potential patient benefit justifies the potential risks of treatment.
Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
No other drug is available in the market than Aviptadil,thats why it got Expanded Access status IMO.
By October company should be able to produce 100000 doses/month as per Dr.Javitt.
BARDA Broad Agency Announcement BAA-18-100-SOL-00003 Amendment 13
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
Click Download this paper at the bottom and see right before the page numbers.You see "BARDA Broad Agency Announcement BAA-18-100-SOL-00003 Amendment 13"
If they are not working with BARDA, why would they publish a paper as per BARDA guidance?.
Huge market and this is a very good news for the company and for the people to recover soon.$$$ RLFTF.Thanks for sharing.
IBM IS ONE OF THE COLLABORATORS OF THE FDA CLINICAL TRIALS
https://clinicaltrials.gov/ct2/show/NCT04311697
That is one of the great indicators where we will be in few weeks,imo $10.
U o Miami Aviptadil clinical trial youtube
OMG -CEO HOPING Aviptadil delivers better results than Remdesivir
https://www.fuw.ch/article/relief-therapeutics-ist-ein-virtuelles-unternehmen/
The hope for effective means has already driven the shares of some small pharmaceutical companies to unimagined heights during the corona crisis. But none shows a more phenomenal price increase of more than 40,000% than Relief Therapeutics. On the one hand, this is due to the fact that it was valued at just CHF 2 million on the stock exchange at the beginning of the year, and on the other hand, it is due to the prospect of a drug against Covid-19.
Since the company announced the first results of its active ingredient Aviptadil (RLF-100) last week, the shares have taken off. In an interview with “Finanz und Wirtschaft”, Chairman of the Board of Directors Raghuram Selvaraju is confident: “We hope that Aviptadil delivers better results than Remdesivir.” Gilead's drug is the first and so far only in a scientific study to have a positive effect on disease progression and has received emergency approval.
NEWS OUT - Several pharmaceutical companies have signed up to distribute Aviptadil.
https://www.fuw.ch/article/relief-therapeutics-ist-ein-virtuelles-unternehmen/
Mehrere Pharma-Unternehmen haben sich für den Vertrieb von Aviptadil gemeldet. «Wir stellen ein reges Interesse fest», sagt Verwaltungsratspräsident Raghuram Selvaraju
English:
Several pharmaceutical companies have signed up to distribute Aviptadil. "We are seeing a lot of interest," says Chairman Raghuram Selvaraju
EXPANDED ACCESS - Gov. is already using Aviptadil and trying to test pregnant women too.
Mobile County Health Department MCHD.org
Mr.Trump's administration FDA approved first Fast Track therapeutic drug RLF-100, why?.Is it not common sense that he would first talk with his FDA head to check whats happening?.Common sense, imo.
Mr.Trump talking about a therapy today,which could be a transfusion or shot, patients come out the hospital in a day or few days,LOL that is RLF-100 imo.And he specifically he would rather go for it instead of waiting on the vaccine.
Watch between 7.50 and 8.10
Pipeline and good information
https://relieftherapeutics.com/pipeline/
Coronavirus Treatment Acceleration Program - 2 drugs EUA approved
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap#keyresources
Only 2 drugs got EUA and RLF-100 is one among those.
NIH is working with both Remdesvir and Aviptadil.Aviptal is more promising than Remdesvir, because all those crital patients who were treated and recovered with Aviptadil were given Remdesvir.
It might receive priority review voucher which could be worth several 100 millions of dollars.
Material Threat Medical Countermeasure working with NIH and other agencies
https://www.trialsitenews.com/rlf-100-aviptadil-associated-with-rapid-respiratory-failure-recovery-among-covid-19-patients/
NeuroRX, Inc. and Relief Therapeutics Holdings AG (SIX:RFL, OTC:RLFTF) “Relief” announced that the investigational therapy RLF-100 (Aviptadil) evidence rapid recovery from respiratory failure in the most critically ill patients with COVID-19. In parallel, an independent group of researchers have reported that Aviptadil blocked replication of SARS-CoV-2 in human lung cells and monocytes. The drug has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies.
First Use Emergency Use IND Houston Methodist Hospital
The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days. Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.
Positive Findings Continue
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.
The clinical findings may be based on evidence that VIP inhibits the replication of the SARS-CoV-2 virus in human lung cells and immune cells (monocytes). The work was reported by Brazilian researchers working in a level-4 biocontainment laboratory. The same researchers reported a case-control study in which patients who survived being on ventilators for COVID-19 had significantly higher levels of VIP in their blood than those who died of respiratory failure.
“No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication,” said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx. “We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month.”
About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the Alveolar Type II cell, which is critical for the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression. (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
About RLF-100
RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said’s original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief’s predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of aviptadil.
V-RT was trading at 25 cents and went upto $17 with no FDA approval.
$86,283,588 $VOLUME - OMG